Testicular Mesothelioma

Testicular Mesothelioma Quick Facts
Affected Site	Tunica vaginalis testis
Proportion of All Mesotheliomas	Less than 1% (0.7% of male mesotheliomas)
Total Published Cases	Approximately 275–289
Median Age at Diagnosis	58–62 years
Documented Asbestos Link	27–38% of cases (varies by study)
Most Common Presentation	Painless scrotal swelling or hydrocele
Preoperative Diagnosis Rate	Very rare (typically incidental)
Most Common Histologic Subtype	Epithelioid (57–60%)
Standard Treatment	Radical inguinal orchiectomy
5-Year Survival Rate	Approximately 49%
10-Year Survival Rate	Approximately 33%
Overall Recurrence Rate	42–53%
TNM Staging System	None specific to testicular mesothelioma

Testicular mesothelioma — formally known as malignant mesothelioma of the tunica vaginalis testis (MMTVT) — is the rarest of the four recognized anatomic types of mesothelioma. First described by Barbera and Rubino in 1957, fewer than 300 cases have been documented in the entire world medical literature over nearly seven decades. The disease arises from the mesothelial cells lining the tunica vaginalis, a serous membrane that surrounds the testis and is derived embryologically from the peritoneum (processus vaginalis).

Among the four mesothelioma types — pleural, peritoneal, pericardial, and testicular — the tunica vaginalis form presents a series of medical paradoxes. It is exceedingly rare yet highly aggressive, with recurrence rates exceeding 50% in some series. Yet it simultaneously offers the most favorable prognosis of any mesothelioma type outside of peritoneal disease treated with CRS/HIPEC, with a 5-year survival rate of approximately 49% — nearly four times that of pleural mesothelioma. Its connection to asbestos exposure, the dominant cause of pleural disease, is documented in only a minority of patients. And its diagnosis is almost never suspected clinically, typically being discovered incidentally during surgery for what was thought to be a benign scrotal condition.

These paradoxes have made MMTVT one of the most scientifically intriguing — and clinically challenging — malignancies in oncology. The complete absence of randomized controlled trials, the lack of a dedicated staging system, and the uncertainty surrounding optimal adjuvant therapy mean that clinical management continues to rely almost entirely on accumulated case series data and expert consensus.

Understanding testicular mesothelioma at a glance:

• 4x higher 5-year survival than pleural disease — testicular mesothelioma patients survive to 5 years at approximately 49% compared to only 12% for pleural mesothelioma
• Comparable long-term survival to treated peritoneal disease — 10-year survival of 33% approaches peritoneal mesothelioma treated with CRS/HIPEC (39%), despite no equivalent multimodal protocol
• 3.4-fold recurrence drop with radical orchiectomy — local recurrence rate of 10.5–11.5% after inguinal orchiectomy compared to 35.7% after hydrocele wall resection alone
• Italian registry detected 2.4x more asbestos exposure — thorough structured interviews found occupational asbestos in 66% of patients versus the 27–38% reported in standard case series reviews
• Epithelioid subtype 30x more common than sarcomatoid — 57–60% of MMTVT cases are epithelioid compared to only 1–2% sarcomatoid, whereas pleural mesothelioma has 10–20% sarcomatoid
• Younger patient distribution than pleural disease — approximately 25% of MMTVT patients are under 45 years of age versus a median age of 71–75 years for pleural mesothelioma
• Left testis affected nearly twice as often as right — 60–65% of cases occur on the left side, possibly reflecting processus vaginalis anatomy
• No survival benefit from adding chemotherapy — median survival of 24 months with surgery alone versus 24 months with surgery plus adjuvant therapy (p = 0.59)
• Diagnosis missed preoperatively in the vast majority of cases — 36% of patients are diagnosed incidentally during surgery for benign conditions, and standard tumor markers (AFP, beta-HCG, LDH) are characteristically normal

Key Facts

Metric	Finding
Total Published Cases	275 patients from 170 publications (Grogg et al., Journal of Cancer Research and Clinical Oncology, 2021); 289 patients from 159 publications (Stella et al., Cancers, 2024)
Proportion of All Mesotheliomas	Less than 1% overall; 0.7% of male mesotheliomas with a standardized incidence rate of 0.095 per million person-years (Nazemi et al., Urology, 2019, n=52 SEER cases)
Median Age at Diagnosis	62 years in both major systematic reviews; range from 6 to 90+ years; approximately 25% of patients younger than 45 (Grogg et al., 2021, n=275; Stella et al., 2024, n=289)
Asbestos Exposure Rate	27–38% in standard reviews; 66% when thorough structured interviews conducted (Italian ReNaM Registry, n=68); asbestos not investigated in 42% of published cases (Vimercati et al., Environmental Health, 2019)
Asbestos Causation Odds Ratio	OR 3.42 (95% CI: 1.93–6.04) for occupational asbestos exposure (Marinaccio et al., Scandinavian Journal of Work, Environment and Health, 2020, case-control study using Italian ReNaM data)
Incidental Discovery Rate	36% diagnosed incidentally during surgery for presumed benign conditions — hydrocelectomy, hernia repair, scrotal exploration (Grogg et al., 2021, 93 of 259 patients with data)
Histologic Subtype Distribution	Epithelioid 57–60%, biphasic 23%, sarcomatoid 1–2%, unspecified 16–18% (Grogg et al., 2021, n=227 with subtype data; Stella et al., 2024, n=289)
5-Year and 10-Year Survival	5-year survival approximately 49%; 10-year survival approximately 33%; median overall survival 24 months (Nazemi et al., Urology, 2019; Plas et al., Cancer, 1998, n=73)
Recurrence Rate	42–53% overall; local recurrence 6–13%, distant metastases 31–35%; median time to local recurrence 17 months; >60% of recurrences within 2 years (Plas et al., 1998; Stella et al., 2024; Grogg et al., 2021)
Most Common Metastatic Sites	Retroperitoneal lymph nodes (48%), lungs (36%), inguinal lymph nodes (27%), peritoneal surfaces (21%) of metastatic cases (Grogg et al., 2021)
Adjuvant Chemotherapy Survival Benefit	No benefit demonstrated — median survival 24 months with surgery alone vs 24 months with surgery plus adjuvant therapy (p = 0.59); cisplatin used in 41%, pemetrexed in 34% of treated patients (Stella et al., 2024, 49 of 289 received adjuvant therapy)
Metastatic Risk Factors	Age 42+ years (OR 3.02), tumor size 49+ mm (OR 6.17), necrosis (OR 8.31), high mitotic index (OR 13.36), angiolymphatic invasion (OR 3.75) — multivariable analysis (Grogg et al., 2021)

How Common Is Testicular Mesothelioma?

Testicular mesothelioma is exceedingly rare. A SEER registry analysis by Nazemi et al. of 52 cases identified over four decades estimated it at 0.7% of all male mesotheliomas, with a standardized incidence rate of 0.095 per million person-years based on Italian registry data. For context, the CDC reported 2,669 total mesothelioma cases in the United States in 2022, meaning testicular mesothelioma accounts for fewer than 20 expected cases annually in the country.

The two largest systematic reviews provide the most comprehensive case inventories. Grogg et al. (2021) analyzed 275 patients from 170 publications spanning the entire literature up to 2019. Stella et al. (2024) compiled the most current review, identifying 289 patients from 159 publications covering 1982 to 2024. Both studies reported a median age at diagnosis of 62 years, though the disease has been documented in patients as young as 6 years of age.

Although testicular mesothelioma most commonly affects men in their sixties, it has a broader age distribution than is commonly appreciated. Plas et al., in their landmark 1998 analysis of 73 patients, found that nearly 50% were aged 55–75 years, 75% were older than 45, and approximately 10% were younger than 25 years. This younger tail of the age distribution contrasts with pleural mesothelioma, where the median age at diagnosis is typically 71–75 years. The wider age range, combined with the low proportion of patients with documented asbestos exposure, has led some researchers to question whether the risk factor profile for testicular mesothelioma may differ fundamentally from that of pleural disease.

What Is the Connection Between Asbestos and Testicular Mesothelioma?

The relationship between asbestos exposure and testicular mesothelioma is significantly weaker and more contentious than the well-established link for pleural disease. Published rates of documented asbestos exposure in MMTVT patients have varied considerably depending on how thoroughly exposure histories were investigated:

Study	Patients with Data	Asbestos Exposure Rate
Grogg et al. (2021)	154 of 275	38%
Stella et al. (2024)	200 of 289	36% (occupational: 26%)
Vimercati et al. (2019)	58% investigated	27.6% direct exposure
Italian ReNaM Registry	68 interviewed	66% occupational exposure

The wide range in these figures — from 27% to 66% — is revealing. The Italian National Mesothelioma Registry (ReNaM) data yielded the highest rate because patients underwent thorough, structured lifetime exposure interviews conducted by trained occupational health specialists. This suggests that superficial history-taking in many published case reports substantially underestimates true exposure. The Vimercati et al. systematic review specifically noted that asbestos exposure was not even investigated in 42% of published cases.

The pathophysiologic mechanism by which inhaled asbestos fibers reach the tunica vaginalis remains uncertain. The tunica vaginalis is an embryologic remnant of the peritoneum (processus vaginalis), which explains why it contains mesothelial cells capable of malignant transformation. Several hypotheses have been proposed: hematogenous or lymphatic dissemination of inhaled fibers from the lungs, transperitoneal migration of ingested fibers through a patent or partially obliterated processus vaginalis, and direct peritoneal extension in patients with concurrent peritoneal exposure.

The Marinaccio et al. case-control study using Italian ReNaM data provided the strongest epidemiological evidence to date, finding a statistically significant odds ratio of 3.42 (95% CI: 1.93–6.04) for occupational asbestos exposure and MMTVT. Other proposed risk factors include long-standing hydrocele, chronic scrotal inflammation, testicular trauma, and, rarely, prior radiation exposure and cryptorchidism.

What Are the Symptoms of Testicular Mesothelioma?

Testicular mesothelioma typically presents with nonspecific scrotal findings that closely mimic common benign conditions, making preoperative diagnosis exceptionally rare. In the Stella et al. systematic review of 289 patients, the most frequent presenting features were scrotal or testicular swelling or mass (65% of patients), hydrocele (55%), scrotal pain (11%), and other presentations including inguinal hernia, hematocele, and epididymitis (8%). The Grogg et al. review found that 94% of patients presented with a painless testicular mass, swelling, or hydrocele.

More than half of cases initially present as recurrent hydrocele — a collection of fluid around the testis that is an extremely common and usually benign condition. The finding of a hydrocele in an older man typically leads to conservative management or elective hydrocelectomy, during which the tumor may be discovered unexpectedly. This pattern of incidental discovery is one of the defining characteristics of the disease: in the Grogg review, 36% of cases (93 of 259 patients with available data) were diagnosed incidentally during surgery for a presumed benign condition, including hydrocelectomy, hernia repair, and other elective scrotal procedures.

A preoperative diagnosis of MMTVT is extremely uncommon. The tumor is seldom considered in the differential diagnosis of a scrotal mass or hydrocele due to its extreme rarity. Most published case reports describe the diagnosis as unexpected, often provoking surprise even among experienced urologists. This diagnostic challenge is compounded by the fact that standard testicular tumor markers — alpha-fetoprotein (AFP), beta-human chorionic gonadotropin (beta-HCG), and lactate dehydrogenase (LDH) — are characteristically normal in MMTVT, a pattern that can be falsely reassuring when evaluating what appears to be a testicular neoplasm.

How Is Testicular Mesothelioma Diagnosed?

Imaging

Scrotal ultrasonography is the first-line imaging modality for evaluating testicular and paratesticular pathology but is frequently nonspecific in MMTVT. Typical ultrasound findings include complex hydrocele, thickened or irregular tunica vaginalis, septations within the fluid collection, and small paratesticular nodules. Suspicious features that should raise clinical suspicion include vascularized nodularity on Doppler imaging, irregular plaques along the tunica, and rapid recurrence of hydrocele after aspiration. In the Stella systematic review, imaging was performed in 195 of 289 cases (68%), with ultrasonography used in 48%, CT scanning in 40%, PET scanning in 6%, and MRI in 5%.

CT scanning and MRI are used primarily for staging purposes — to detect retroperitoneal lymphadenopathy, pulmonary metastases, and peritoneal spread. These modalities do not reliably distinguish MMTVT from other paratesticular neoplasms on pre-surgical imaging alone. Contrast-enhanced ultrasound (CEUS) has been proposed as a promising modality for characterizing testicular masses but lacks specific validated criteria for MMTVT.

Tumor Markers

A critical diagnostic feature of MMTVT is that standard testicular germ cell tumor markers are characteristically normal. In the Grogg review, among 52 patients with specific marker data, AFP was elevated in only 1 patient (2%), beta-HCG in 2 (4%), and LDH in 3 (6%). Normal tumor markers in a patient with a testicular or paratesticular mass should broaden the differential diagnosis beyond germ cell tumors to include non-germ cell pathology such as mesothelioma, particularly in patients with known or possible asbestos exposure history.

Pathology and Immunohistochemistry

Definitive diagnosis requires histopathologic examination of the orchiectomy specimen with immunohistochemistry (IHC). The IHC profile of MMTVT mirrors that of pleural mesothelioma, with positive mesothelial markers including calretinin (the most reliable), WT-1, CK5/6, D2-40, and AE1/AE3 (broad-spectrum cytokeratin), and negative carcinoma markers including CEA, claudin-4, and MOC-31.

The International Mesothelioma Interest Group recommends using at least two positive mesothelial markers and two negative epithelial markers, plus a broad-spectrum cytokeratin stain, as part of the initial IHC panel. Additionally, BAP1 loss and CDKN2A deletion testing are increasingly important for distinguishing malignant mesothelioma from well-differentiated papillary mesothelial tumors (WDPMT), a benign entity that requires fundamentally different management.

Histologic Subtypes

Subtype	Grogg et al. (2021)	Stella et al. (2024)
Epithelioid	130/227 (57%)	174/289 (60%)
Biphasic	53/227 (23%)	65/289 (23%)
Sarcomatoid	4/227 (2%)	4/289 (1%)
Unspecified malignant	40/227 (18%)	46/289 (16%)

The predominance of epithelioid histology (57–60%) and the very low proportion of sarcomatoid disease (1–2%) contribute to the relatively favorable prognosis of MMTVT compared to pleural mesothelioma, where sarcomatoid histology is more common.

Is There a Staging System for Testicular Mesothelioma?

There is no standard staging system specifically designed for MMTVT. The extreme rarity of the disease — fewer than 300 total published cases — has precluded the development and validation of dedicated staging criteria. In clinical practice, general mesothelioma staging concepts and SEER extent-of-disease categorizations (localized, regional, distant) are used descriptively.

The Nazemi et al. SEER analysis applied tumor-extent (T) staging and demonstrated its prognostic significance: patients with T1 disease had median survival that was not reached (favorable), while those with T4 disease had overall survival of only 1.7 years and disease-specific survival of 1.8 years (p = 0.002 and p < 0.001, respectively). Tumors 4 cm or larger in diameter were associated with significantly worse overall survival (p = 0.025).

Grogg et al. identified additional risk factors for metastatic disease using multivariable analysis: age 42 years or older (odds ratio 3.02), tumor size 49 mm or larger (OR 6.17), presence of necrosis (OR 8.31), high mitotic index (OR 13.36), and angiolymphatic invasion (OR 3.75). Cases are also classified by histologic subtype and by whether the tumor involves the tunica vaginalis only or has extended to the tunica albuginea, testicular parenchyma, epididymis, spermatic cord, or scrotal wall. The development of a standardized staging system and evidence-based treatment guidelines remains a critical unmet need, with a 2025 expert consensus publication representing an early step toward standardization.

What Are the Treatment Options for Testicular Mesothelioma?

Radical Inguinal Orchiectomy (Standard of Care)

Radical inguinal orchiectomy is the cornerstone of treatment for MMTVT and the only therapeutic modality with demonstrated curative potential. In the Stella systematic review, 216 of 289 patients (75%) underwent radical surgery, with orchiectomy alone performed in most cases and hemiscrotectomy with or without inguinal lymphadenectomy in a minority. The Grogg review similarly reported radical surgical management in 62–75% of cases.

Key surgical principles have been established through accumulated case series experience. Primary hemiscrotectomy and en-bloc orchiectomy are recommended when MMTVT is suspected preoperatively, although this clinical scenario is uncommon. When the diagnosis is made incidentally after hydrocelectomy, completion hemiscrotectomy is recommended due to the risk of tumor seeding at the surgical site. Scrotal biopsy is actively discouraged for the same reason. The importance of adequate primary surgery is underscored by the finding of Plas et al. that local recurrence was 35.7% after hydrocele wall resection alone, compared to 10.5% after scrotal orchiectomy and 11.5% after inguinal orchiectomy.

Retroperitoneal Lymph Node Dissection

The role of retroperitoneal lymph node dissection (RPLND) remains debated. Retroperitoneal lymph nodes are the most common site of metastatic disease, identified in 48% of patients with metastases. However, in the Grogg review, all 21 patients who underwent lymph node dissection as monotherapy — without additional chemotherapy or radiation — experienced disease progression. Current evidence does not support routine RPLND, although it may be considered in select cases with documented retroperitoneal nodal disease, particularly when combined with other treatment modalities.

Adjuvant Chemotherapy

Adjuvant chemotherapy has been administered to a minority of MMTVT patients, with no demonstrated survival benefit in systematic review data. In the Stella review, 49 patients (17%) received adjuvant therapy, and median survival was identical in both groups — 24 months for surgery alone versus 24 months for surgery plus adjuvant therapy (p = 0.59). The most commonly used regimens are borrowed from pleural mesothelioma protocols: cisplatin plus pemetrexed is the most frequent combination (cisplatin used in 41% and pemetrexed in 34% of chemotherapy-treated patients), followed by doxorubicin (21%) and carboplatin (10%).

Despite the lack of systematic evidence, isolated case reports have described complete remission in metastatic settings with aggressive multimodal therapy, including one patient who achieved remission with six cycles of cisplatin/pemetrexed followed by pemetrexed maintenance. A recent report documented partial response to first-line immunotherapy (nivolumab plus ipilimumab) in a biphasic MMTVT case, suggesting that immune checkpoint inhibition may offer a future treatment avenue for this rare disease.

Radiation Therapy

Radiation therapy has been used in very limited cases of MMTVT, with radiation fields typically including the scrotum, retroperitoneal lymph nodes, and inguinal lymph nodes at doses of 25–60.5 Gy. Evidence for radiation remains extremely limited and inconclusive: in the Grogg review, 6 of 11 patients (55%) who received radiation therapy subsequently relapsed. Radiation is not considered standard therapy but may have a role in selected cases as part of multimodal treatment, particularly for local control after surgery in high-risk patients.

What Is the Prognosis for Testicular Mesothelioma?

Recurrence Rates

MMTVT has a notably high recurrence rate that represents one of its most challenging clinical features. The Plas et al. landmark analysis reported an overall recurrence rate (local plus distant) of 52.5%, with more than 60% of recurrences developing within the first two years of follow-up. The Stella review found disease relapse in 120 of 289 patients (42%), predominantly as distant metastases (102 patients, 35%) rather than local recurrence (18 patients, 6%). The Grogg review reported local recurrence in 13% and metastatic disease in 31% of patients, with a median time to local recurrence of 17 months.

The most common metastatic sites are retroperitoneal lymph nodes (48% of metastatic cases), lungs (36%), inguinal lymph nodes (27%), and peritoneal surfaces (21%). Local recurrence itself is a strong risk factor for subsequent metastatic disease, with an odds ratio of 4.35 in the Grogg analysis.

Survival Data

Despite its aggressive biology, MMTVT carries a paradoxically more favorable prognosis than other mesothelioma types:

Metric	Testicular	Pleural	Peritoneal	Pericardial
5-year survival	~49%	~12%	~65% (with CRS/HIPEC)	~9%
10-year survival	~33%	Not reported	~39%	Not reported
Median overall survival	~24 months	8–12 months	Variable	6 months
Median survival (metastatic)	18 months	—	—	—

The Plas landmark review reported a median survival of 23 months overall, decreasing to 14 months in cases with documented recurrence. Nazemi et al. found that median survival was not reached for T1 disease, indicating that early-stage disease carries the most favorable outlook.

Prognostic Factors

Factor	Effect	Evidence
Epithelioid histology	Favorable	Biphasic OS 1.5 years vs. not reached for epithelioid
Tumor size < 4 cm	Favorable	Tumors ≥ 4 cm associated with worse OS (p = 0.025)
T1 disease	Favorable	Median OS not reached
Complete surgical resection	Favorable	Surgery is the only modality with curative potential
Younger age	Favorable	Significant in univariate analysis (p < 0.01)
Spermatic cord/scrotum invasion	Unfavorable	OR 3.21 for local recurrence
Necrosis, high mitotic index	Unfavorable	Strongly associated with metastatic disease
Local recurrence	Unfavorable	OR 4.35 for subsequent metastatic disease

Why Does Testicular Mesothelioma Have Better Survival Than Pleural?

The survival paradox of testicular mesothelioma — a 5-year survival rate of approximately 49% versus approximately 12% for pleural disease, despite high recurrence rates — has generated considerable scientific interest. Several factors likely contribute to this phenomenon:

Surgical resectability. The scrotal location allows for complete surgical resection via radical inguinal orchiectomy, whereas pleural mesothelioma involves diffuse disease across the large pleural surface area that is rarely amenable to complete macroscopic resection. In MMTVT, 62% of cases are organ-confined at diagnosis, enabling R0 (margin-negative) resection in many patients.

Earlier detection through incidental discovery. Although preoperative diagnosis is exceptionally rare, many cases are discovered incidentally during surgery for benign conditions such as hydrocele or hernia. This pattern of incidental surgical discovery may catch the disease at an earlier stage than the typically advanced pleural mesothelioma at clinical presentation, where patients often have extensive disease by the time symptoms prompt medical evaluation.

Favorable histologic distribution. MMTVT has a high proportion of epithelioid histology (~60%) and a very low rate of sarcomatoid histology (~1–2%). Epithelioid mesothelioma consistently carries the best prognosis across all anatomic sites, while sarcomatoid disease — the most treatment-resistant subtype — is rare in testicular mesothelioma but accounts for a larger share of pleural cases.

Younger patient population. While the median age at diagnosis is similar to pleural mesothelioma, the wider age distribution includes a notable proportion of patients under 45 years of age (approximately 25% based on interquartile range data). Younger age is an independent favorable prognostic factor in mesothelioma, and this demographic pattern may contribute to better overall outcomes.

Organ-confined biology. The tunica vaginalis is a small, encapsulated serosal surface. When disease remains limited to this structure, the biological behavior may be inherently less aggressive than pleural disease, which involves a large serosal cavity with direct access to mediastinal structures, pulmonary vasculature, and lymphatic drainage pathways that facilitate widespread dissemination.

What Are the Legal Options for Testicular Mesothelioma Patients?

Patients diagnosed with testicular mesothelioma can pursue the same legal channels available to other mesothelioma patients — including personal injury and wrongful death lawsuits, asbestos trust fund claims, veterans' benefits, and workers' compensation — though the legal landscape presents distinct challenges due to the disease's rarity and the more complex causation evidence.

The most significant legal challenge is the lower documented rate of asbestos exposure in MMTVT patients compared to pleural mesothelioma. With only 27–38% of cases documenting asbestos exposure in most reviews, the evidentiary burden on plaintiffs to establish causation is higher. However, several factors strengthen the legal position for patients with documented exposure histories. The Vimercati systematic review demonstrated that asbestos exposure was not even investigated in 42% of published cases, and the Italian ReNaM registry — which conducted thorough structured lifetime exposure interviews — found occupational asbestos exposure in 66% of interviewed patients. This substantial underreporting in the medical literature suggests that the true exposure rate is much higher than commonly cited figures indicate.

The Marinaccio et al. case-control study provides direct epidemiological evidence of a statistically significant association between occupational asbestos exposure and MMTVT, with an odds ratio of 3.42. Furthermore, the severity of any mesothelioma diagnosis and its strong general association with asbestos — combined with the shared molecular features between testicular and pleural mesothelioma — typically support compensation claims even for rarer subtypes. Experienced mesothelioma attorneys who understand the unique aspects of testicular mesothelioma are essential for assembling the medical expert testimony and scientific evidence needed to establish causation in these complex cases.

Free, Confidential Case Evaluation Call (866) 222-9990 or visit dandell.com/contact-us No upfront fees • Experienced representation • National practice

Frequently Asked Questions

What is testicular mesothelioma?

Testicular mesothelioma, formally known as malignant mesothelioma of the tunica vaginalis testis (MMTVT), is the rarest form of mesothelioma. It develops in the tunica vaginalis, a thin membrane surrounding the testis that is derived embryologically from the peritoneum. Fewer than 300 cases have been documented in the world medical literature since the disease was first described in 1957. Despite its rarity, MMTVT is an aggressive cancer with a recurrence rate exceeding 40%, though it paradoxically offers the best prognosis of any mesothelioma type outside of peritoneal disease treated with CRS/HIPEC.

Is testicular mesothelioma caused by asbestos?

The asbestos connection is weaker and more controversial than for pleural mesothelioma. Most reviews document asbestos exposure in 27–38% of cases, compared to 70–80% for pleural disease. However, thorough exposure investigations by the Italian National Mesothelioma Registry found rates as high as 66%, suggesting underreporting. A 2020 case-control study found a statistically significant 3.42-fold increased risk with occupational asbestos exposure. While asbestos is likely a contributing factor, other risk factors — including chronic hydrocele, inflammation, and possibly genetic predisposition — may also play roles.

How is testicular mesothelioma diagnosed?

The diagnosis is almost never made before surgery. Most cases are discovered incidentally during hydrocelectomy, hernia repair, or scrotal exploration. Standard testicular tumor markers (AFP, beta-HCG, LDH) are characteristically normal, which distinguishes MMTVT from germ cell tumors. Definitive diagnosis requires histopathologic examination of the orchiectomy specimen with immunohistochemistry using a panel of mesothelial markers (calretinin, WT-1, CK5/6, D2-40).

What is the treatment for testicular mesothelioma?

Radical inguinal orchiectomy is the standard of care and the only treatment with curative potential. Completion hemiscrotectomy is recommended when MMTVT is discovered incidentally after hydrocelectomy. Adjuvant chemotherapy (typically cisplatin plus pemetrexed) has not demonstrated a survival benefit in systematic review data but is sometimes administered for high-risk or metastatic disease. Radiation therapy evidence is limited and inconclusive. A 2025 expert consensus publication represents the first effort to establish standardized treatment guidelines.

What is the survival rate for testicular mesothelioma?

Testicular mesothelioma has the most favorable prognosis of the four mesothelioma types (excluding peritoneal disease treated with CRS/HIPEC). The 5-year survival rate is approximately 49%, and the 10-year survival rate is approximately 33%. The median overall survival is about 24 months, dropping to 14 months in patients who develop recurrence. Favorable prognostic factors include epithelioid histology, tumor size under 4 cm, T1 disease, complete surgical resection, and younger age.

Why does testicular mesothelioma have better survival than pleural mesothelioma?

Several factors contribute to this paradox. The scrotal location allows for complete surgical resection, unlike the diffuse pleural disease that is rarely curable by surgery. Many cases are caught incidentally during surgery for benign conditions, potentially at earlier stages. The high proportion of epithelioid histology (60%) and very low sarcomatoid rate (1–2%) favor better outcomes. A younger patient population and the small, encapsulated nature of the tunica vaginalis may also contribute to the more favorable biology.

Can testicular mesothelioma patients file legal claims?

Yes. Patients with documented asbestos exposure can pursue personal injury lawsuits, asbestos trust fund claims, veterans' benefits, and workers' compensation. While the lower asbestos exposure rate creates a higher evidentiary burden than for pleural mesothelioma, the Marinaccio case-control study (OR 3.42) provides strong epidemiological support, and the general severity of mesothelioma diagnosis typically supports compensation claims. Experienced mesothelioma attorneys are essential for these complex cases.

⚠ Statute of Limitations Warning: Filing deadlines vary by state from 1-6 years from diagnosis. Texas allows 2 years from diagnosis or discovery. Contact an attorney immediately to preserve your rights.

Get Help

Testicular mesothelioma patients and families can connect with experienced legal and medical advocates:

• Danziger & De Llano provides free case evaluations for mesothelioma patients with or without documented asbestos exposure — call (866) 222-9990
• Mesothelioma Lawyer Center offers resources on legal rights and compensation for all mesothelioma types
• Mesothelioma.net provides information on testicular mesothelioma treatment and prognosis

Quick Statistics

• First described in the medical literature — Barbera and Rubino published the initial case report of malignant mesothelioma of the tunica vaginalis testis in 1957
• Youngest documented patient — the disease has been reported in patients as young as 6 years of age, far below the typical median age of 62 years
• 2025 expert consensus milestone — the first-ever expert consensus publication on MMTVT diagnosis and treatment was published in 2025, representing an initial step toward standardized clinical guidelines
• Immunotherapy case reports emerging — a partial response to first-line nivolumab plus ipilimumab was documented in a biphasic MMTVT case, suggesting immune checkpoint inhibition as a potential future treatment avenue
• Geographic concentration of published research — the Italian National Mesothelioma Registry (ReNaM) has produced some of the most comprehensive epidemiological data, including the largest case-control study of asbestos and MMTVT
• Calretinin is the most reliable diagnostic marker — among mesothelial immunohistochemistry markers (calretinin, WT-1, CK5/6, D2-40), calretinin has the highest sensitivity for confirming mesothelioma origin
• Well-differentiated papillary mesothelioma must be excluded — WDPMT is a benign entity requiring fundamentally different management; BAP1 loss and CDKN2A deletion testing help distinguish malignant from benign mesothelial tumors
• Molecular profiling identifies recurrent genetic losses — CDKN2A and NF2 loss have been identified in MMTVT, mirroring molecular alterations seen in pleural mesothelioma
• Case report publication has accelerated in recent decades — the two largest systematic reviews compiled 170 publications through 2019 (Grogg et al.) and 159 publications through 2024 (Stella et al.), reflecting growing recognition of this rare entity